4D Molecular Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from 4D Molecular Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-45.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 70% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$40Sales grew 2,623% in 3 years, but profit fell: $40 less profit per $100 of extra sales.
Lower than 81% of Healthcare companies in United States.
Asset Productivity Ratio
+2623% / +116%In 3 years sales changed by +2623% while total assets changed by +116%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-19.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 54% of Healthcare companies in United States.
Cash Cushion Ratio
+58%Cash, after subtracting all debt, equals 58% of its market value (net cash).
Higher than 80% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
4D Molecular Therapeutics, Inc. made a loss over the last year. 4D Molecular Therapeutics, Inc. owes $0.17 for every $1 it owns. 4D Molecular Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
Loss4D Molecular Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.61The share price is 1.61 times 4D Molecular Therapeutics, Inc.'s book value per share, lower than 65% of Healthcare companies in United States.
Market cap
$655 MThe total market value of all of 4D Molecular Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$408 MWhat 4D Molecular Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.38Net worth divided by the number of shares. The share price of $11.85 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
-43.2%4D Molecular Therapeutics, Inc. lost 43.2% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
Owes vs Owns
0.17×4D Molecular Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
None4D Molecular Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+230195%Revenue rose 230195% in the year to Dec 2025, and grew 201% a year on average over 3 years.
Profit growth
Loss4D Molecular Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-164.4%4D Molecular Therapeutics, Inc. lost $164 for every $100 of revenue.
Cash vs debt
Net cash4D Molecular Therapeutics, Inc. held $381 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For 4D Molecular Therapeutics, Inc.: $655 M ÷ $408 M (30 Jun 2026) = 1.6.
What is 4D Molecular Therapeutics, Inc.'s return on equity?
4D Molecular Therapeutics, Inc. lost 43.2% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
How much does 4D Molecular Therapeutics, Inc. owe compared with what it owns?
4D Molecular Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does 4D Molecular Therapeutics, Inc. pay a dividend?
No. 4D Molecular Therapeutics, Inc. does not currently pay a dividend.
Is 4D Molecular Therapeutics, Inc.'s revenue growing?
Revenue rose 230195% in the year to Dec 2025, and grew 201% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.